Skip to content
Catalyst

Astragalus membranaceusFinding

Astragalus membranaceus decreases fasting blood glucose

lowersModerate evidenceFinding

01 · The sentence it was drawn from

“The Astragalus combined RAAS blocker therapy showed a significantly larger decrease in FPG compared with the control group (WMD: −0.28, 95% CI [−0.40, −0.17], p < 0.00001; Figure 7).”
Quoted verbatim from Efficacy of astragalus combined with renin-angiotensin-aldosterone system blockers in the treatment of stage III diabetic nephropathy: a systematic review and meta-analysis.
This finding among the 111 findings on its endpoint

Astragalus membranaceus

Fasting blood glucose

lowers

Effect as reported

−0.28mean difference

CI −0.4 to −0.17

Who
Adults with stage III diabetic nephropathy (Mogensen staging); 15 pooled Chinese trials in which both arms received the same ACE inhibitor or ARB and only one arm also received astragalus; routes pooled (injection and oral herb)
Dose studied
Pooled; astragalus injection 20 to 60 mL per day or oral astragalus 20 to 180 g per day, added to an ACE inhibitor or ARB, 1 to 48 weeks

Moderate evidencePMID 38836372 · 2024

02 · The study

Study
meta-analysis
Duration
not reported

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

Renal failure
What else it reported2 findings · 0 compounds · 2 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M704C2B5DGDNP86H58697660